Vascular endothelial growth factor selectively targets boronated dendrimers to tumor vasculature

Molecular Cancer Therapeutics

Volumn 4, Issue 9, 2005, Pages 1423-1429

  Backer, Marina V ^a   Gaynutdinov, Timur I ^a   Patel, Vimal ^a   Bandyopadhyaya, Achintya K ^b   Thirumamagal, B T S ^b   Tjarks, Werner ^b   Barth, Rolf F ^b   Claffey, Kevin ^c   Backer, Joseph M ^a  

^a SIBTECH INC   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORON; DENDRIMER; HYBRID PROTEIN; POLYAMIDOAMINE; THIOL GROUP; VASCULOTROPIN; BORON DERIVATIVE; POLYAMINE; VASCULAR ENDOTHELIAL GROWTH FACTOR A, HUMAN; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOPHOSPHORYLATION; BREAST CARCINOMA; CELL STRAIN; CELL STRAIN HEK293; CELL TRANSPORT; CONFOCAL MICROSCOPY; CROSS LINKING; ENDOTHELIUM CELL; GENE OVEREXPRESSION; GENETIC ENGINEERING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; MOUSE; NEAR INFRARED SPECTROSCOPY; NEUTRON CAPTURE THERAPY; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN TARGETING; RECEPTOR UPREGULATION; TUMOR VASCULARIZATION; ANIMAL; BAGG ALBINO MOUSE; CELL CULTURE; CELL PROLIFERATION; CHEMISTRY; DRUG EFFECT; EXPERIMENTAL NEOPLASM; FEMALE; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); VASCULAR ENDOTHELIUM; VASCULARIZATION;

ANIMALS; BORON COMPOUNDS; BORON NEUTRON CAPTURE THERAPY; CELL PROLIFERATION; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; NEOVASCULARIZATION, PATHOLOGIC; POLYAMINES; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33644701668     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-05-0161     Document Type: Article

References (38)

1. Barth RF, Coderre JA, Vicente MGH, Blue TE. Boron neutron capture therapy of cancer: current status and future prospects. Clin Cancer Res 2005;11:3987-4002.
2. Soloway AH, Tjarks W, Barnum BA, et al. The chemistry of neutron capture therapy. Chem Rev 1998;98:1515-62.
3. Hartman T, Carlsson J. Radiation dose heterogeneity in receptor and antigen mediated boron neutron capture therapy. Radiother Oncol 1994; 31:61-75.
4. Pouget JP, Mather SJ. General aspects of the cellular response to low-and high-LET radiation. Eur J Nucl Med 2001;28:541-61.
5. Barth RF, Yang W, Adams DM, et al. Molecular targeting of the epidermal growth factor receptor for neutron capture therapy of gliomas. Cancer Res 2002;62:3159-66.
6. Barth RF, Wu G, Yang W, et al. Neutron capture therapy of epidermal growth factor positive gliomas using boronated cetuximab (IMC-C225) as a delivery agent. Appl Radiat Isot 2004;61:899-903.
7. Capala J, Barth RF, Bendayan M, et al. Boronated epidermal growth factor as a potential targeting agent for boron neutron capture therapy of brain tumors. Bioconjugate Chem 1996;7:7-15.
8. Yang W, Barth RF, Rotaru JH, et al. Boron neutron capture therapy of brain tumors: enhanced survival following intracarotid injection of sodium borocaptate with or without blood-brain barrier disruption. Int J Radiat Oncol 1997;37:663-72.
9. Yang W, Barth RF, Wu G, et al. Development of a syngeneic rat brain tumor model expressing EGFRvlll and its use for molecular targeting studies with monoclonal antibody L8A4. Clin Cancer Res 2005;11: 341-50.
10. Yang W, Barth RF, Adams DM, Soloway AH. Intratumoral delivery of boronated epidermal growth factor for neutron capture therapy of brain tumors. Cancer Res 1997;57:4333-9.
11. Yang W, Barth RF, Wu G, et al. Boronated epidermal growth factor as a delivery agent for neutron capture therapy of EGFR positive gliomas. Appi Radiat Isot 2004;61:981-5.
12. Gedda L, Olsson P, Ponten J, Carlsson J. Development and in vitro studies of epidermal growth factor-dextran conjugates for boron neutron capture therapy. Bioconjugate Chem 1996;7:584-91.
13. Barth RF, Adams DM, Soloway AH, Alam F, Darby MV. Boronated starburst dendrimer-monoclonal antibody immunoconjugates: evaluation as a potential delivery system for neutron capture therapy. Bioconjugate Chem 1994;5:58-66.
14. Wu G, Barth RF, Yang W, et al. Site-specific conjugation of boron-containing dendrimers to anti-EGF receptor monoclonal antibody cetuximab (IMC-C225) and its evaluation as a potential delivery agent for neutron capture therapy. Bioconjugate Chem 2004; 15:185-94.
15. Liu L, Barth RF, Adams DM, Soloway AH, Reisfeld RA. Bispecific antibodies as targeting agents for boron neutron capture therapy of brain tumors. J Hernatother 1995;4:477-83.
16. Liu L, Barth RF, Adams DIM, Soloway AH, Reisfeld RA. Critical evaluation of bispecific antibodies as targeting agents for boron neutron capture therapy of brain tumors. Anticancer Res 1996; 16:2581-7.
17. Shukla S, Wu G, Chatterjee M, et al. Synthesis and biological evaluation of folate receptor-targeted boronated PAMAM dendrimers as potential agents for neutron capture therapy. Bioconjugate Chem 2003; 14:158-67.
18. Folkman J. Angiogenesis in cancer,vascular, rheumatoid and other disease. Nat Med 1995;1:27-31.
19. Veikkola T, Karkkainen M, Claesson-Welsh L, Alitalo K. Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Res 2000;60:203-12.
20. Brown LF, Berse B, Jackman RW, et al. Expression of vascular permeability factor (vascular enclothelial growth factor) and its receptors in breast cancer. Hum Pathol 1995;26:86-91.
21. Couffinhal T, Kearney M, Witzenbichler B, et al. Vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) in normal and artherosclerotic human arteries. Am J Pathol 1997; 150:1673-85.
22. Jackson MW, Roberts JS, Heckford SE, et al. A potential autocrine role for vascular endothelial growth factor in prostate cancer. Cancer Res 2002;62:854-9.
23. Dev IK, Dornsife RE, Hopper TM, et al. Antiturnour efficacy of VEGFR2 tyrosine kinase inhibitor correlates with expression of VEGF and its receptor VEGFR2 in tumor models. Br J Cancer 2004;91:1391-8.
24. Arora N, Maood R, Zheng T, Cai J, Smith L, Gill PS. Vascular endothelial growth factor chimeric toxin is highly active against endothelial cells. Cancer Res 1999;59:183-8.
25. Backer MV, Backer JM.Targeting endothelial cells overexpressing VEGFR-2: selective toxicity of Shiga-like toxin-VEGF fusion proteins. Bioconjugate Chem 2001; 12:1066-73.
26. Veenendaal LM, Jin H, Ran S, et al.In vitro and in vivo studies of a VEGF121/rGelonin chimeric fusion toxin targeting the neovasculature of solid tumors. Proc Natl Acad Sci U S A 2002;99:7866-71.
27. Alam F, Soloway AH, Barth RF, Mafune N, Adams DM, Knoth WH. Boron neutron capture therapy: linkage of a boronated macromolecule to monoclonal antibodies directed against tumor-associated antigens. J Med Chem 1989;32:2326-30.
28. Mujumdar RB, Ernst LA, Mujumdar SR, Lewis CJ, Waggoner AS. Cyanine dye labeling reagents: sulfoindocyanine succinimidyl esters. Bioconjugate Chem 1993;4:105-11.
29. Backer MV, Gaynutdinov TI, Gorshkova II, et al. Humanized docking system for assembly of targeting drug delivery complexes. J Control Release 2003;89:499-511.
30. Backer MV, Gaynutdinov TI, Aloise R, Przekop K, Backer JM. Engineering S-protein fragments of bovine ribonuclease A for targeted drug delivery. Protein Expr Purif 2002;26:455-61.
31. Backer MV, Gaynutdinov T, Patel V, Jehning B, Myshkin E, Backer JM. Adapter protein for site-specific conjugation of payloads for targeted drug delivery. Bioconjugate Chem 2004;15:1021 -9.
32. Backer MV, Backer JIM. Functionally active VEGF fusion proteins. Protein Expr Purif 2001;23:1-7.
33. Backer MV, Elliot J, Gaynutdinov TI, Backer JIM. Assembly of targeting complexes driven by a single-chain antibody. J Immunol Methods 2004;289:37-45.
34. Koning GA, Fretz MM, Woroniecka U, Storm G, Krijger GC. Targeting liposomes to tumor endothelial cells for neutron capture therapy. Appl Radiat Isot 2004;61:963-7.
35. Picard FJ, Bergeron MG. Rapid molecular theranostics in infectious diseases. Drug Discov Today 2002;7:1092-101.
36. Gumbleton M, Stephesn DJ. Coming out of the dark: the evolving role of fluorescence imaging in drug delivery research. Adv Drug Deliv Rev 2005; 57:5-15.
37. Blankenberg FG, Mandl S, Cao Y-A, et al.Tumor imaging using a standardized radiolabeled adapter protein docked to vascular endothelial growth factor (VEGF). J Nucl Mad 2004;45:1373-80.
38. Maeda H, Wu J, Sawa T, Matsumura Y, Hori KJ.Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 2000;65:271-84.